Verastem Oncology in Collaboration Agreement With Amgen
September 20 2021 - 8:03AM
Dow Jones News
By Chris Wack
Verastem Oncology said it has entered into a clinical
collaboration agreement with Amgen Inc. to evaluate the combination
of VS-6766, Verastem Oncology's investigational dual RAF/MEK
inhibitor, with Amgen's KRAS G12C inhibitor Lumakras sotorasib in
KRAS G12C-mutant non-small cell lung cancer.
The biopharmaceutical company said the Phase 1/2 trial would
evaluate the safety, tolerability and efficacy of VS-6766 in
combination with Lumakras in patients with KRAS G12C-mutant NSCLC
who have not been previously treated with a KRAS G12C inhibitor as
well as in patients who have progressed on a KRAS G12C
inhibitor.
The study would investigate the potential benefits of a more
complete vertical blockade of the RAS pathway with the combination
of VS-6766 with Lumakras in KRAS G12C-mutant locally advanced or
metastatic NSCLC.
Verastem Oncology said it expects to initiate the clinical trial
with VS-6766 and Lumakra by the end of 2021.
On Sunday, Verastem Oncology said it saw positive data from its
ongoing investigator-sponsored Phase 1/2 study investigating
VS-6766 in combination with defactinib, its FAK inhibitor, in
patients with low grade serous ovarian cancer.
Verastem shares were up 24%, to $3.42, in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 20, 2021 07:48 ET (11:48 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024
